| Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates |
Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.35 per share a year ago. |
zacks.com |
2025-05-12 13:15:39 |
Czytaj oryginał (ang.) |
| Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights |
– Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 – – Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 – – Cash position of $217 million as of March 31, 2025; cash runway extended into 1Q 2027 with reduction of preclinical spend – BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2025, and provided business highlights. “Accumulating data continue to support TNG462 as the potential best-in-class PRMT5 inhibitor,” said Barbara Weber, M.D. |
globenewswire.com |
2025-05-12 11:00:00 |
Czytaj oryginał (ang.) |
| Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release |
Tango Therapeutics (TNGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-05-05 15:05:38 |
Czytaj oryginał (ang.) |
| Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 |
BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call. |
globenewswire.com |
2025-05-01 11:00:00 |
Czytaj oryginał (ang.) |
| Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 |
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been accepted as poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, in Chicago, Illinois. |
globenewswire.com |
2025-03-25 18:30:00 |
Czytaj oryginał (ang.) |
| Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates |
Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.32 per share a year ago. |
zacks.com |
2025-02-27 11:20:34 |
Czytaj oryginał (ang.) |
| Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights |
– TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer – – Investigational New Drug (IND) application for TNG456, a next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, cleared by FDA. Phase 1/2 enrollment expected to begin 1H 2025 – – Clinical collaboration with Eli Lilly to evaluate TNG456 in combination with CDK4/6 inhibitor Verzenio ® (abemaciclib) established – – Data update from ongoing TNG462 monotherapy trial expected in 2025 with focus on pancreatic and lung cancer – – Cash position of $258 million as of December 31, 2024, with cash runway expected to fund operations into 3Q 2026 – BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported financial results for the fourth quarter and full year ended December 31, 2024, and provided business highlights. |
globenewswire.com |
2025-02-27 09:00:00 |
Czytaj oryginał (ang.) |
| Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference |
BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim SMID Cap Biotechnology Conference on Wednesday, February 5, 2025 at 10:00 AM ET. |
globenewswire.com |
2025-01-30 09:00:00 |
Czytaj oryginał (ang.) |
| Tango Therapeutics: Chance For A Short Squeeze |
Tango Therapeutics is a growing cancer drug development company with partners such as Gilead Sciences. Given the high short interest and the low number of shares outstanding, I expect a short squeeze to occur, which could lead to an increase in TNGX's share price thereafter. Despite the negative sentiment, recent institutional selling and call option activity suggest potential value accumulation and positive momentum for TNGX. |
seekingalpha.com |
2025-01-23 07:44:05 |
Czytaj oryginał (ang.) |
| Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective December 2, 2024, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 187,500 shares of its common stock and 31,250 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement. |
businesswire.com |
2024-12-03 09:00:00 |
Czytaj oryginał (ang.) |
| Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference |
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Adam Crystal, M.D., Ph.D., President, Research & Development of Tango Therapeutics, is scheduled to present at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024 at 1:30 PM ET. A live webcast of the presentation will be available under the "Events. |
businesswire.com |
2024-11-27 09:00:00 |
Czytaj oryginał (ang.) |
| Tango Therapeutics, Inc. (TNGX) Reports Q3 Loss, Tops Revenue Estimates |
Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.23 per share a year ago. |
zacks.com |
2024-11-06 11:16:11 |
Czytaj oryginał (ang.) |
| Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data |
Tango Therapeutics, Inc. offers high-risk, high-reward exposure to PRMT5-inhibitor drugs, with two candidates, TNG908 and TNG462, targeting MTAP-deleted cancers, a substantial market opportunity. TNGX stock volatility is influenced by competitors' PRMT5 data, with recent fluctuations driven by Amgen and Mirati's clinical results. Tango's financial stability is supported by >$300M in cash, a Gilead partnership, and a funding runway until 2027, covering key clinical readouts. |
seekingalpha.com |
2024-09-10 16:45:11 |
Czytaj oryginał (ang.) |
| Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Tops Revenue Estimates |
Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.23 per share a year ago. |
zacks.com |
2024-08-07 13:55:58 |
Czytaj oryginał (ang.) |
| Earnings Preview: Tango Therapeutics, Inc. (TNGX) Q2 Earnings Expected to Decline |
Tango Therapeutics (TNGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-07-29 15:06:18 |
Czytaj oryginał (ang.) |
| Tango Therapeutics (TNGX) Surges 6.7%: Is This an Indication of Further Gains? |
Tango Therapeutics (TNGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2024-07-23 10:26:07 |
Czytaj oryginał (ang.) |
| Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last? |
Tango Therapeutics (TNGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term. |
zacks.com |
2024-06-14 10:10:16 |
Czytaj oryginał (ang.) |
| Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference |
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to present at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 2:40 PM ET. A live webcast of the presentation will be available under the "Events &a. |
businesswire.com |
2024-06-05 11:00:00 |
Czytaj oryginał (ang.) |
| Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program |
STOCKHOLM , May 23, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir's licensee, Tango Therapeutics (NASDAQ: TNGX; Tango), has announced that the phase 1/2 clinical trial of TNG348, a novel USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts. TNG348 is a novel USP1 (ubiquitin-specific protease 1) inhibitor, for the treatment of BRCA1/2-mutant and other homologous recombination deficiency (HRD)+ cancers, and has been developed by Tango from the preclinical USP1 program licensed from Medivir in 2020. |
prnewswire.com |
2024-05-23 13:18:00 |
Czytaj oryginał (ang.) |
| Tango Therapeutics to stop development of cancer therapy |
Tango Therapeutics said on Thursday it would stop the development of its experimental cancer therapy due to liver toxicity experienced by patients in an early-to-mid stage trial. |
reuters.com |
2024-05-23 11:19:15 |
Czytaj oryginał (ang.) |
| Tango Therapeutics Announces Discontinuation of TNG348 Program |
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that it will discontinue development of its TNG348 program. “Patient safety is always our first priority and based on emerging data from the TNG348 dose escalation study, we have made the decision to discontinue further development of this molecule due to liver toxicity experienced by p. |
businesswire.com |
2024-05-23 11:00:00 |
Czytaj oryginał (ang.) |
| Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Misses Revenue Estimates |
Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.32 per share a year ago. |
zacks.com |
2024-05-08 13:10:22 |
Czytaj oryginał (ang.) |
| Will Tango Therapeutics, Inc. (TNGX) Report Negative Q1 Earnings? What You Should Know |
Tango Therapeutics (TNGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-05-07 15:01:04 |
Czytaj oryginał (ang.) |
| Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective April 1, 2024, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 139,453 shares of its common stock and 23,698 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Pl. |
businesswire.com |
2024-04-01 20:48:00 |
Czytaj oryginał (ang.) |
| Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates |
Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago. |
zacks.com |
2024-03-18 11:10:25 |
Czytaj oryginał (ang.) |
| Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights |
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided business highlights. “In 2023, we made meaningful progress developing precision oncology treatments and now have four ongoing phase 1/2 clinical trials. These treatments have the potential to reach. |
businesswire.com |
2024-03-18 09:00:00 |
Czytaj oryginał (ang.) |
| Tango Therapeutics to Participate in Upcoming Investor Conferences |
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in March. Leerink Partners 2024 Global Biopharma Conference Date: Tuesday, March 12, 2024 Time: 3:00 PM ET Location: Miami, F. |
businesswire.com |
2024-03-06 09:00:00 |
Czytaj oryginał (ang.) |
| Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024 |
BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that one abstract has been selected for an oral minisymposium and seven abstracts have been accepted as poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California. |
globenewswire.com |
2024-03-05 18:47:00 |
Czytaj oryginał (ang.) |
| Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference |
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 11:30 AM EST. |
globenewswire.com |
2024-01-31 09:00:00 |
Czytaj oryginał (ang.) |